• 
  Marie Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, Constance Lamy, Magali Lacroix-Triki, et al.. Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. British Journal of Cancer, In press, ⟨10.1038/s41416-024-02804-6⟩. ⟨hal-04683939⟩
• 
  Arnaud de Muyt, Alexandra Pyatnitskaya, Jessica Andreani, Lepakshi Ranjha, Claire Ramus, et al.. A meiotic XPF–ERCC1-like complex recognizes joint molecule recombination intermediates to promote crossover formation. Genes and Development, 2018, 32 (3-4), pp.283-296. ⟨10.1101/gad.308510.117⟩. ⟨hal-02191280⟩
• 
  Alice Mogenet, Fabrice Barlesi, Benjamin Besse, Stefan Michiels, Maryam Karimi, et al.. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. Lung Cancer, 2022, 169, pp.31-39. ⟨10.1016/j.lungcan.2022.05.004⟩. ⟨hal-03925563⟩
• 
  Cathy Pichol-Thievend, Oceane Anezo, Aafrin Pettiwala, Guillaume Bourmeau, Remi Montagne, et al.. VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance. Nature Communications, 2024, 15 (1), pp.3602. ⟨10.1038/s41467-024-47985-z⟩. ⟨hal-04648492⟩
• 
  Stéphanie Solier, Sebastian Müller, Tatiana Cañeque, Antoine Versini, Leeroy Baron, et al.. Discovery of a druggable copper-signaling pathway that drives cell plasticity and inflammation. Nature, 2023, 617, pp.386-394. ⟨10.1101/2022.03.29.486253⟩. ⟨hal-04061061⟩

66

91 %